Roche Acquires Poseida Therapeutics to Advance CAR-T Therapies

On November 26, 2024, Roche announced its definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company based in San Diego. Poseida is known for its pioneering work in donor-derived CAR-T cell therapies. The company's research and development portfolio includes both preclinical and clinical-stage off-the-shelf CAR-T therapies, targeting a range of diseases including hematological cancers, solid tumors, and autoimmune conditions. Poseida’s advanced manufacturing capabilities and technology platforms are also part of the acquisition, strengthening Roche's position in the CAR-T therapy space.

This acquisition enhances the ongoing partnership between Roche and Poseida, which began in 2022 through a collaboration and licensing agreement focused on advancing off-the-shelf CAR-T therapies for hematological malignancies. The acquisition is seen as a significant step forward in Roche’s strategic vision to develop the next generation of CAR-T cell therapies, with a focus on improving potency, safety, and accessibility for broader patient populations.

Roche’s commitment to this partnership is underscored by its goal to deliver transformative therapies in oncology, immunology, and neurology. Levi Garraway, Roche’s Head of Product Development and Chief Medical Officer, expressed confidence in the progress made with Poseida’s technologies and emphasized the potential for these therapies to become first-in-class treatments. The merger will accelerate the development of these innovative cell therapies, bringing them closer to commercialization and addressing pressing medical needs.